PCI Biotech Holding ASA (OSL:PCIB) GF Score: 6/100 (As of Jul. 04, 2026) — 79% Below Median


OSL:PCIB PCI Biotech Holding ASA OSL:PCIB
6 GF Score
Price kr0.12
! 1 Warning Sign
View Full Analysis

What is PCI Biotech Holding ASA GF Score?

PCI Biotech Holding ASA OSL:PCIB -12.21% 6 GF Score is 6 as of Jul. 04, 2026, which is 79% below its 10-year median of 29.00. GuruFocus rates OSL:PCIB with a GF Score™ of 6/100. The stock has 1 warning sign investors should review.

PCI Biotech Holding ASA has the GF Score of 6, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 7/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes PCI Biotech Holding ASA might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

PCI Biotech Holding ASA  (OSL:PCIB) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

PCI Biotech Holding ASA GF Score Related Terms

OSL:PCIB vs VRTX, REGN, ALNY: GF Score Comparison

For the Biotechnology subindustry, PCI Biotech Holding ASA's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PCI Biotech Holding ASA GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's GF Score distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's GF Score falls into.


OSL:PCIB
6GF Score
PCI Biotech Holding ASA OSL:PCIB
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 6 mean?
PCI Biotech Holding ASA (OSL:PCIB) has a GF Score of 6 as of Jul. 04, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on PCI Biotech Holding ASA and its competitors. This is 79% below median its historical median of 29.00. Over the past decade, PCI Biotech Holding ASA's GF Score has ranged from 6.00 to 44.00.
Is PCI Biotech Holding ASA's GF Score too high?
PCI Biotech Holding ASA's current GF Score of 6 is 79% below median its 10-year median of 29.00. Over the past 10 years, this metric has ranged from a low of 6.00 to a high of 44.00. Overall, PCI Biotech Holding ASA has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does PCI Biotech Holding ASA's GF Score compare to VRTX and REGN?
PCI Biotech Holding ASA's GF Score of 6 can be compared against companies in the Biotechnology industry. Historically, PCI Biotech Holding ASA's own GF Score has ranged from 6.00 to 44.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on PCI Biotech Holding ASA and its competitors. PCI Biotech Holding ASA's current GF Score is 6, which is 79% below median its own 10-year median of 29.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PCI Biotech Holding ASA stock overvalued right now?
PCI Biotech Holding ASA (OSL:PCIB) has a current GF Score of 6. The current GF Score is 6, which is 79% below median its 10-year median of 29.00. PCI Biotech Holding ASA's overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For PCI Biotech Holding ASA (OSL:PCIB), the current GF Score is 6 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PCI Biotech Holding ASA Business Description

Address Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.
6GF Score

Get the complete analysis for OSL:PCIB

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.12
Price